“As the pharmaceutical market looks like it will be extremely dynamic in 2012, we prefer to go for a conservative version, with moderate sales growth of around 5%,” said Dan Zamonea, Roche’s general manager.
Zamonea was appointed head of management center Romania with Swiss giant Hoffmann la Roche as of July 1, 2011. In this position he runs a ten-country region (Romania included) with more than EUR400 million in annual sales.
Zamonea cites the data of market research company Cegedim Romania, which show that Roche’s sales stood at approximately RON734 million in the first ten months of 2011.
Roche’s portfolio includes only prescription drugs used in treating such conditions as anemia, cancer, influenza, hepatitis, AIDS, among others.
Zamonea says 2012 will be an important year for the company as it will focus on the launch of two new cancer drugs. He is also optimistic about the trend of the market in 2012 and 2013.
Market research company IMS Health has recently announced its 2012 forecast of a return to double-digit growth for the market, after growth of only 7% in 2011. IMS Health’s optimism is partly based on the new health care bill recently put up for public debate.
IMS’ statistics put Roche on the top spot among pharmaceutical companies in Romania in the first eleven months of 2011, ahead of Sanofi. The Romanian market is analyzed by two market research companies, Cegedim and IMS Health. (EUR1=RON4.3434)
(English version by Loredana Fratila-Cristescu)